Indol-3-ylcycloalkyl Ketones: Effects of N1 Substituted Indole Side Chain Variations on CB2 Cannabinoid Receptor Activity

被引:118
作者
Frost, Jennifer M. [1 ]
Dart, Michael J. [1 ]
Tietje, Karin R. [1 ]
Garrison, Tiffany R. [1 ]
Grayson, George K. [1 ]
Daza, Anthony V. [1 ]
El-Kouhen, Odile F. [1 ]
Yao, Betty B. [1 ]
Hsieh, Gin C. [1 ]
Pai, Madhavi [1 ]
Zhu, Chang Z. [1 ]
Chandran, Prasant [1 ]
Meyer, Michael D. [1 ]
机构
[1] Abbott Labs, Neurol Dis Res, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA
关键词
CENTRAL-NERVOUS-SYSTEM; ACID AMIDE HYDROLASE; IN-VITRO; PHARMACOLOGICAL CHARACTERIZATION; AGONIST; PAIN; INHIBITION; ACTIVATION; AM1241; DESIGN;
D O I
10.1021/jm901214q
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Several 3-acylindoles with high affinity for the CB2 cannabinoid receptor and selectivity over the CB1 receptor have been prepared. A variety of 3-acyl substituents were investigated, and the tetramethylcyclopropyl group was found to lead to high affinity CB2 agonists (5, 16). Substitution at the N1-indole position was then examined. A series of aminoalkylindoles was prepared and several Substituted aminoethyl derivatives were active (23-27, 5) at the CB2 receptor. A study of N1 nonaromatic side chain variants provided potent agonists at the CB2 receptor (16, 35-41, 44-47, 49-54, and 57-58). Several polar side chains (alcohols, oxazolidinone) were well-tolerated for CB2 receptor activity (41, 50), while others (amide, acid) led to weaker or inactive compounds (55 and 56). N1 aromatic side chains also afforded several high affinity CB2 receptor agonists (61, 63, 65, and 69) but were generally less potent in all in vitro CB2 functional assay than were nonaromatic side chain analogues.
引用
收藏
页码:295 / 315
页数:21
相关论文
共 54 条
[1]   Cannabinoids control spasticity and tremor in a multiple sclerosis model [J].
Baker, D ;
Pryce, G ;
Croxford, JL ;
Brown, P ;
Pertwee, RG ;
Huffman, JW ;
Layward, L .
NATURE, 2000, 404 (6773) :84-87
[2]  
BARTH F, 2006, Patent No. 7138424
[3]   Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury [J].
Batkai, Sandor ;
Osei-Hyiaman, Douglas ;
Pan, Hao ;
El-Assal, Osama ;
Rajesh, Mohanraj ;
Mukhopadhyay, Partha ;
Hong, Feng ;
Harvey-White, Judith ;
Jafri, Anjum ;
Hasko, Gyorgy ;
Huffman, John W. ;
Gao, Bin ;
Kunos, George ;
Pacher, Pal .
FASEB JOURNAL, 2007, 21 (08) :1788-1800
[4]  
Bell M.R., 1986, Eur. Patent, Patent No. 171037
[5]   CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms [J].
Beltramo, M ;
Bernardini, N ;
Bertorelli, R ;
Campanella, M ;
Nicolussi, E ;
Fredduzzi, S ;
Reggiani, A .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2006, 23 (06) :1530-1538
[6]  
Benito C, 2003, J NEUROSCI, V23, P11136
[7]   Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis [J].
Benito, Cristina ;
Romero, Juan Pablo ;
Tolon, Rosa Maria ;
Clemente, Diego ;
Docagne, Fabian ;
Hillard, Cecilia J. ;
Guaza, Camen ;
Romero, Julian .
JOURNAL OF NEUROSCIENCE, 2007, 27 (09) :2396-2402
[8]   ACYLATION OF THE ZINC SALT OF INDOLE [J].
BERGMAN, J ;
VENEMALM, L .
TETRAHEDRON, 1990, 46 (17) :6061-6066
[9]   Role of cannabinoid CB2 receptors in glucose homeostasis in rats [J].
Bermudez-Silva, Francisco Javier ;
Sanchez-Vera, Irene ;
Suarez, Juan ;
Serrano, Antonia ;
Fuentes, Esther ;
Juan-Pico, Pablo ;
Nadal, Angel ;
Rodriguez de Fonseca, Fernando .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 565 (1-3) :207-211
[10]   Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers [J].
Bingham, B. ;
Jones, P. G. ;
Uveges, A. J. ;
Kotnis, S. ;
Lu, P. ;
Smith, V. A. ;
Sun, S-C ;
Resnick, L. ;
Chlenov, M. ;
He, Y. ;
Strassle, B. W. ;
Cummons, T. A. ;
Piesla, M. J. ;
Harrison, J. E. ;
Whiteside, G. T. ;
Kennedy, J. D. .
BRITISH JOURNAL OF PHARMACOLOGY, 2007, 151 (07) :1061-1070